BAX and PKCα modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia

Clinical Cancer Research

Volumn 6, Issue 4, 2000, Pages 1401-1409

  Kornblau, Steven M ^a,c   Vu, Ha T ^a   Ruvolo, Peter ^b   Estrov, Zeev ^a   O'Brien, Susan ^a   Cortes, Jorge ^a   Kantarjian, Hagop ^a   Andreeff, Michael ^a   May, W Stratford ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE C; BAX PROTEIN, HUMAN; ISOENZYME; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ONCOPROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADOLESCENT; CELL CULTURE; CELL STRAIN HL 60; CELL STRAIN K 562; CHROMOSOME ANALYSIS; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; REMISSION; SURVIVAL; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CYTOGENETIC ANALYSIS; FEMALE; HL-60 CELLS; HUMANS; ISOENZYMES; K562 CELLS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLY(ADP-RIBOSE) POLYMERASES; PROGNOSIS; PROTEIN KINASE C; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; REMISSION INDUCTION; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED;

EID: 0033624762     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Yang, E., and Korsmeyer, S. J. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood, 88: 386-401, 1996.
2. Cohen, G. M. Caspases: the executioners of apoptosis. Biochem. J., 326: 1-16, 1997.
3. Rowan, S., and Fisher, D. E. Mechanisms of apoptotic cell death. Leukemia (Baltimore), 11: 457-465, 1997.
4. Kroemer, G. The proto-oncogene bcl-2 and its role in regulating apoptosis. Nat. Med., 3: 614-620, 1997.
5. Webb, S. J., Harrison, D. J., and Wyllie, A. H. Apoptosis: an overview of the process and its relevance in disease. Adv. Pharmacol., 41: 1-34, 1997.
6. Reed, J. C. Bcl-2 family proteins: strategies for overcoming chemoresistance in cancer. Adv. Pharmacol., 41: 501-532, 1997.
7. Konopleva, M., Zhao, S., Xie, Z., Seagall, H., Younes, A., Claxton, D. F., Estrov, Z., Kornblau, S. M., and Andreeff, M. Apoptosis. Molecules and mechanisms. In: A. J. P. Veerman, R. Pieters, and G. J. L. Kaspers (eds.), Drug Resistance in Leukemia and Lymphoma III. Amsterdam: Plenum Publishing Corp., 1999.
8. Oltvai, Z. N., Milliman, C. L., and Korsmeyer, S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell, 74: 609-619, 1993.
9. May, W. S., Tyler, P. G., Ito, T., Armstrong, D. K., Qatasha, K. A., and Davidson, N. E. lnterleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 α in association with suppression of apoptosis. J. Biol. Chem., 209: 26865-26870, 1994.
10. Ito, T., Deng, X., Carr, B., and Strauss, E. Bcl-2 phosphorylation required for anti-apoptosis function. J. Biol. Chem., 272: 11671-11673, 1997.
11. Ruvolo, P. P., Deng, X., Carr, B. K., and May, W. S. A functional role for mitochondrial protein kinase C-α in bcl2 phosphorylation and suppression of apoptosis. J. Biol. Chem., 273: 25436-25442, 1998.
12. del Peso, L., Gonzalez-Garcia, M., Page, C., Herrera, R., and Nunez, G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science (Washington DC), 278: 687-689, 1997.
13. Maung, Z. T., MacLean, F. R., Reid, M. M., Pearson, A. D. J., Proctor, S. J., Hamilton, P. J., and Hall, A. G. The relationship between bcl-2 expression and response to chemotherapy in acute leukaemia. Br. J. Haematol., 88: 105-109, 1994.
14. Campos, L., Rouault, J-P., Sabido, O., Oriol, P., Roubi, N., Vasselon, C., Archimbaud, E., Magaud, J-P., and Guyotat, D. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response in chemotherapy. Blood, 81: 3091-3096, 1993.
15. Lauria, F., Raspador, D., Rondelli, D., Ventura, M. A., Facchini, M., Visani, G., Forconi, F., and Tura, S. High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate. Leukemia (Baltimore), 11: 2075-2078, 1997.
16. Karakas, T., Maurer, U., Weidmann, E., Miething, C. C., Hoelzer, D., and Bergmann, L. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann. Oncol., 9: 159-165, 1998.
17. Kornblau, S. M., Thall, P. F., Estrov, Z., Walterscheid, M., Patel, S., Theriault, A., Keating, M. J., Kantarjian, H., Estey, E., and Andreeff, M. The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin. Cancer Res., 5: 1758-1766, 1999.
18. Lepelley, P., Soenen, V., Preudhomme, C., Merlat, A., Cosson, A., and Fenaux, P. bcl-2 expression in myelodysplastic syndromes and its correlation with hematological features, p53 mutations and prognosis. Leukemia (Baltimore), 9: 726-730, 1995.
19. Charpin, C., Garcia, S., Bonnier, P., Martini, F., Andrac, L., Horschowski, N., Lavaut, M-N., and Allasia, C. bcl-2 automated and quantitative immunocytochemical assays in breast carcinomas: correlation with 10-year follow-up. J. Clin. Oncol., 16: 2025-2031, 1998.
20. Campana, D., Coustan-Smith, E., Manabe, A., Buschle, M., Raimondi, S. C., Behm, F. G., Ashmun, R., Arico, M., Biondi, A., and Pui, C-H. Prolonged survival of B-lineage acute lymphoblastic leukemia cells is accompanied by overexpression of bcl-2 protein. Blood, 81: 1025-1031, 1993.
21. Coustan-Smith, E., Kitanaka, A., Pui, C-H., McNinch, L., Evans, W. E., Raimondi, S. C., Behm, F. G., Arico, M., and Campana, D. Clinical relevance of bcl-2 overexpression in childhood acute lymphoblastic leukemia. Blood, 87: 1140-1146, 1996.
22. Volm, M., Zintl, F., Edler, L., and Sauerbrey, A. Prognostic value of protein kinase C, proto-oncogene products and resistance-related proteins in newly diagnosed childhood acute lymphoblastic leukemia. Med. Pediatr. Oncol., 28: 117-126, 1998.
23. Kornblau, S. M., Andreeff, M., Hu. S-X., Xu, H-J., Patel, S., Theriault, A., Koller, C., Kantarjian, H., Estey, E. H., Deisseroth, A. B., and Benedict, W. F. Low and maximally phosphorylated levels of the retinoblastoma protein conter poor prognosis in newly diagnosed acute myelogenous leukemia: a prospective study. Clin. Cancer Res., 4: 1955-1963, 1998.
24. Estrov, Z., Thall, P., Talpaz, M., Estey, E. H., Kantarjian, H., Harris, D., Van, Q., Walterscheid, M., and Kornblau, S. M. Caspase 2 and caspase 3 protein levels as predictors for survival in acute myelogenous leukemia. Blood, 92: 3090-3097, 1998.
25. Le, X. F., Groner, Y., Levanon, D., Kornblau, S., Hittelman, W., Arlinghaus, R. B., and Chang, K. S. AML2, a nuclear phosphoprotein with a possible role in myeloid differentiation and leukemogenesis. Blood, 90 (Suppl. 1): 46a, 1997.
26. Le, X. F., Claxton, D., Kornblau, S., Fan, Y., Mu, Z. M., and Chang. K. S. Characterization of the ETO and AML1-ETO proteins involved in 8;21 translocation in acute myelogenous leukemia. Eur. J. Haematol., 60: 217-225, 1998.
27. Claxton, D., Xie, Q., Patel, S., Deisseroth, A. B., and Kornblau, S. M. The gene product of the CBFB-MYH11, Leukemia (Baltimore), 1479-1485, 1996.
28. Deng, X., Ito, T., Carr, B., Mumby, M., and May, W. S. Reversible phosphorylation of BCL2 following IL-3 or bryostatin 1 is mediated by the direct interaction with protein phosphatase 2a. J. Biol. Chem., 273: 34157-34163, 1998.
29. Snedecor, G. W., and Cochran, W. G. Statistical Methods, Ed. 7, Iowa: Iowa State University Press, 1980.
30. 2 measures the discrepancy between observation and hypothesis. J. R. Stat. Soc., 87: 442-450, 1924.
31. Mehta, C. R. The exact analysis of contingency tables in medical research. Stat. Methods Med. Res., 3: 135-156, 1994.
32. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observation. J. Am. Stat. Assoc., 53: 457-481, 1958.
33. Mantel, N. Evaluation of survival data and two new rank order statistics arising in its consideration. J. R. Stat. Soc., 50: 63-170, 1966
34. Cox, D. R. Regression models and life tables. J. R. Stat. Soc., 34: 187-220, 1972.
35. Fleming, T. R., and Harrington, D. P. Counting Processes and Survival Analysis. New York: John Wiley & Sons, Inc., 1991.
36. Altman, D. G., Lausen, B., Sauerbrei, W., and Schumacher, M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J. Natl. Cancer Inst., 86: 829-835. 1994.
37. Schiffer, C. A., Lee, E., Tomiyasu, T., Wiernik, P., and Testa, J. Prognostic impact of cytogenetic abnormalities in patients with de nova acute nonlymphocytic leukemia. Blood, 73: 263-270, 1989.
38. Smith, T. L., and McCredie, K. Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia. Leukemia (Baltimore), 3: 257-263, 1989.
39. Keating, M. J., Cork, A., Broach, Y., Smith, T., Walters, R. S., McCredie, K. B., Trujillo, J., and Freireich, E. J. Toward a clinically relevant cytogenetic classification of AML. Leuk. Res., 11: 119-133, 1987.
40. Kawakami, K., Futami, H., Takahara, J., and Yamaguchi, K. UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. Biochem. Biophys. Res. Commun., 219: 778-783, 1996.
41. Shao, R. G., Shimizu, T., and Pommier, Y. 7-Hydroxystaurosporine (UCN-01) induces apoptosis in human colon carcinoma and leukemia cells independent of p53. Exp. Cell Res., 234: 388-397, 1997.